ATGAM Sterile Solution contains lymphocyte immune globulin, anti-thymocyte globulin [equine]. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric IgG, from hyperimmune serum of horses immunized with human thymus lymphocytes. ATGAM is a transparent to slightly opalescent aqueous protein solution.

Administer ATGAM intravenously and use with concomitant immunosuppressants. The recommended dose is 10 to 15 mg/kg daily intravenously for 14 days. Additional alternate-day therapy up to a total of 21 doses may be given. The recommended dose is 10 to 20 mg/kg daily intravenously for 8 to 14 days.

Anaphylaxis has been reported with the use of ATGAM. ATGAM can cause potentially life‑threatening anaphylaxis when injected intravenously. Monitor patients for signs and symptoms of anaphylaxis during infusion and for at least 24 hours after infusion

ATGAM is indicated for the treatment of moderate to severe aplastic anemia in patients unsuitable for bone marrow transplantation (see section 5.2 Pharmacodynamic properties). The usefulness of ATGAM has not been demonstrated in patients with aplastic anemia who are suitable candidates for bone marrow transplantation or in patients with aplastic

ATGAM® (lymphocyte immune globulin, anti-thymocyte globulin [equine] sterile solution) This product information is intended only for residents of the United States. for Consumers: ATGAM - U.S. Medical Information Page - patient information, ways to contact Pfizer Medical & other resources; for Healthcare professionals:

ATGAM sterile solution contains lymphocyte immune globulin, anti-thymocyte globulin (equine). It is the purified, concentrated, and sterile gamma globulin, primarily monomeric IgG, from hyperimmune serum of horses immunized with human thymus lymphocytes. ATGAM is a transparent to slightly opalescent aqueous protein solution.

Renal allograft rejection Aplastic anemia (moderate to severe) in patients unsuitable for bone marrow transplantation. Limitations of Use: The usefulness of ATGAM has not been demonstrated in...

Administer ATGAM intravenously and use with concomitant immunosuppressants. The recommended dose is 10 to 5 mg/kg daily intravenously for 14 days. Additional alternate-day therapy up to a total of 21 doses may be given.

2023年12月12日 · Atgam has induced instances of partial or complete haematologic recovery and improved survival in patients with aplastic anaemia of known or suspected immunologic aetiology in patients who are unsuitable for bone marrow transplant.

By providing your email address and/or phone number, you are agreeing to receive transactional, product, supply information communications from Pfizer Inc. Message and data rates may apply for SMS messages sent to your mobile phone.